Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

In 1967, pioneering work by Ruth Nussenzweig demonstrated for the first time that irradiated
sporozoites of the rodent malaria parasite Plasmodium berghei protected mice against a …

Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

Immunization of humans with whole sporozoites confers complete, sterilizing immunity
against malaria infection. However, achieving consistent safety while maintaining …

Controlled human malaria infection (CHMI) by mosquito bite has been used to assess anti-
malaria interventions in> 1,500 volunteers since development of methods for infecting …

Background Human monoclonal antibodies might offer an important new approach to
reduce malaria morbidity and mortality. In the first two parts of a three-part clinical trial, the …

Despite global efforts to control malaria, the illness remains a significant public health threat.
Currently, there is no licensed vaccine against malaria, but an efficacious vaccine would …